Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Biomarin Pharmaceutical Q4 2023 Adj EPS $0.49 Beats $0.23 Estimate, Sales $646.20M Beat $636.88M Estimate

Author: Benzinga Newsdesk | February 22, 2024 05:04pm
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.23 by 113.04 percent. The company reported quarterly sales of $646.20 million which beat the analyst consensus estimate of $636.88 million by 1.46 percent. This is a 20.21 percent increase over sales of $537.54 million the same period last year.

Posted In: BMRN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist